Jean-Pascal Machiels
让-帕斯卡尔·马切尔斯
MD, PhD
Professor of Oncology; Head, Department of Medical Oncology肿瘤学教授；内科肿瘤学系主任
👥Biography 个人简介
Jean-Pascal Machiels, MD, PhD is Professor of Oncology at the Université Catholique de Louvain and Head of the Department of Medical Oncology at Cliniques Universitaires Saint-Luc in Brussels, Belgium. (Note: though based in Belgium, his work is published and presented extensively in French-language and pan-European oncology.) He is one of Europe's most prominent head and neck cancer investigators, known for critical contributions to cetuximab and anti-EGFR therapy, and for co-leading the EXTREME trial that established cetuximab plus platinum-5FU as the first-line standard of care in R/M HNSCC prior to the immunotherapy era. Dr. Machiels also led KEYNOTE-412, a pivotal phase III trial evaluating pembrolizumab plus chemoradiotherapy in locally advanced HNSCC. He chairs the ESMO Head and Neck Cancer Clinical Practice Guidelines Committee and is a leading voice in European HNSCC clinical trials design.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EXTREME Trial: Cetuximab + Platinum/5-FU in R/M HNSCC
Co-led the EXTREME phase III trial establishing the addition of cetuximab to platinum-based chemotherapy as the first regimen to improve overall survival in first-line recurrent/metastatic HNSCC, defining the standard of care for over a decade.
KEYNOTE-412: Pembrolizumab + CRT in Locally Advanced HNSCC
Led KEYNOTE-412, the phase III trial evaluating pembrolizumab added to concurrent chemoradiotherapy in locally advanced HNSCC, generating key evidence on the role of immune checkpoint blockade in the curative-intent treatment setting.
ESMO HNSCC Clinical Guidelines
Chaired the European Society for Medical Oncology (ESMO) Head and Neck Cancer Guidelines Committee, developing evidence-based practice standards that guide oncologists across Europe and internationally.
Novel EGFR and Immunotherapy Combinations
Led phase I/II investigations combining anti-EGFR monoclonal antibodies with novel immunotherapy agents, identifying rational combination strategies based on EGFR-mediated immunosuppression within the tumor microenvironment.
Representative Works 代表性著作
Cetuximab plus platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: the EXTREME randomised phase III trial
Annals of Oncology (2010)
Analysis of the EXTREME trial demonstrating cetuximab added to platinum/5-FU chemotherapy significantly improved overall survival in R/M HNSCC, establishing a new first-line standard.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412)
The Lancet Oncology (2023)
Phase III trial of pembrolizumab versus placebo added to CRT in locally advanced HNSCC, providing important data on immune checkpoint integration in curative-intent HNSCC treatment.
ESMO Clinical Practice Guidelines for head and neck cancers: diagnosis, treatment and follow-up
Annals of Oncology (2020)
Comprehensive ESMO guidelines for HNSCC covering staging, treatment by disease stage, systemic therapy selection, and follow-up, serving as the primary European clinical reference.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 让-帕斯卡尔·马切尔斯 的研究动态
Follow Jean-Pascal Machiels's research updates
留下邮箱，当我们发布与 Jean-Pascal Machiels（Cliniques Universitaires Saint-Luc / Université Catholique de Louvain）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment